Centre for Cellular and Molecular Platforms (C-CAMP) co-authored a publication in Nature Communications (Nature Portfolio) featuring two new antibiotics in Phase I and advanced pre-clinical stages of trials, co-authored by Bugworks Research Inc., GangaGen Biotechnologies, Venus Remedies Limited, and partner institutions.

Centre for Cellular And Molecular Platforms (C-CAMP) is an initiative of Dept of Biotechnology, Ministry of Science and Technology, Govt. of India, with a mandate to be an enabler of cutting edge Life Science Research and Innovation. C-CAMP is also a member of the Bangalore Life Sciences Cluster (BLiSC). We facilitate Bioscience Research and Entrepreneurship by providing Research, Development, Training and Services in state-of-the-art Technology Platforms. As a part C-CAMP's mandate of promoting entrepreneurship and innovation, C-CAMP has created and fostered an entrepreneur-friendly culture in and around Academic/Research environment through its involvement in Seed Funding Schemes for Startups, Entrepreneur Mentorship program and Bio-Incubation facility. At C-CAMP, we have established State-Of-The-Art Platform Technologies which are essential requirements for success and leadership in the field of Life Sciences. C-CAMP allows Investigators to use Techniques as tools and not be limited by Technological barriers while pursuing challenging scientific questions. For more information, please visit our website at: http://ccamp.res.in/ | Follow us on Twitter: https://twitter.com/ccamp_bangalore | Interact with us through our Facebook page: https://www.facebook.com/CCAMPBangalore/